HOYA Corporation (HOCPY) Fair Value & Analysis
Healthcare · US · Market cap $59.7B
HOYA Corporation
HOCPY · US
Fair value as of: Jul 16, 2026
From 24 valuation models · updated 25 days ago
Fair value updated Jul 16, 2026, revised from $101.00 to $161.16 (+59.6%) since Jun 24, 2026. Share price +9.9% over the past month.
A strong business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- A fairly wide model range ($107.77 to $201.96) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.
How to read this chart
60‑month range $81.13 – $188.89 · fair‑value band $107.77 – $201.96 · the $163.59 price screens above the $161.16 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 16, 2026.
Analysis
HOYA Corporation (HOCPY) currently trades at $163.59, while our model-based Fair Value estimate is $161.16, implying the stock looks roughly 1.5% fairly valued today. The Quality Score stands at 86/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, HOYA Corporation generated revenue of $948B at a net margin of 26.7%. Revenue grew 15.1% year over year. It earns a return on equity of 25.1%. The balance sheet holds a net cash position of $534B. Fundamentals as of Jul 16, 2026
Our scenario range runs from $107.77 (bear case) to $201.96 (bull case); at $163.59, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 13% below its 52-week high and 46% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -1%, HOCPY screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings ($101.70) versus Asset-Based ($13.52). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 83 · Market factors (momentum, volatility) 60
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
HOYA Corporation, a med-tech company, provides high-tech and medical products in the Japan, Asia, the Americas, Europe, and internationally. The company operates through two segments: Life Care, and Information and Communications.
Full company description
HOYA Corporation, a med-tech company, provides high-tech and medical products in the Japan, Asia, the Americas, Europe, and internationally. The company operates through two segments: Life Care, and Information and Communications. It offers life care products, including eyeglasses; contact lenses; medical endoscopes; intraocular lenses; laparoscopic surgical instruments; automatic endoscope cleaning equipment; and other medical related products, such as prosthetic ceramic fillers and metallic implants for orthopedics, brain surgery, and dentistry. The company also operates Eyecity, a specialty retailer of contact lenses. In addition, it provides information technology products, such as mask blanks and photomasks for manufacturing semiconductor chips; glass disks for hard disk drives; and imaging related products that comprise optical glasses/optical lenses, colored glass filters, and UV light resources. Further, the company engages in research, development, manufacture, and sale of photomasks for manufacturing flat panel displays. HOYA Corporation was founded in 1941 and is headquartered in Shinjuku, Japan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
HOYA Corporation reported revenue of $1.0T in FY2026 versus $670B in FY2022, a compound +10.7%/yr. Reported net income was $268B in FY2026, compounding +13.0%/yr from FY2022.
Watch HOCPY: get an alert when its fair value changes →
Earlier news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Hoya (TSE:7741) Stock After New FDA Clearance Weighing Rich Valuation Against Growth Potential
- Hoya (TSE:7741) Stock After 60% Rise Is The Rally Losing Steam?
- HOYA FDA Clearance Adds New Endoscopy Catalyst To Valuation Debate
- DKILY vs. HOCPY: Which Stock Is the Better Value Option?
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare HOYA Corporation with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is HOYA Corporation (HOCPY) overvalued or undervalued?
What is the fair value of HOCPY?
What is the quality score of HOCPY?
What is the revenue of HOYA Corporation (HOCPY)?
What is the net profit margin of HOCPY?
Does HOYA Corporation pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track HOYA Corporation and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.